Nanovaccines and cellular vaccines based on Listeria monocytogenes and their applications in biomedicine

Group members Research lines Articles Projects Other publications

1.- Cerebral listeriosis and neonatal listeriosis models: (PI: Dr. C. Alvarez Domínguez/Grants: SAF2006- 08968, SAF2009-08695, SAF2012-34203). To establish cerebral and neonatal listeriosis models to analyze specific virulence factors of the pathogen targeted to microglia and design a cerebral listeriosis vaccine. This study implies the characterization of microglia phagosomes using differential proteomics (col. C. Gil. UCM) and examine new adyuvants for neonatal vaccines (col. M. Fresno, CBMSO).

2.- Listeria based dendritic vaccines loaded with peptides against infectious agents. (PI: Dr. C. Alvarez Dominguez and Co-PI: Dra. S. Ya- ñez Diaz/Grants: SAF2009-08695 y SAF2012-34203 and Approved Clinical Study: CEIC-Acta 19/2014- 2014.228). A Listeria based dendritic vaccine loaded with peptides from virulence factors specific of Listeria (LLO) and common to Mycobacterium smegmatis (GAPDH) will be used to examine experimental prophylactic measures against both bacteria. Moreover, we are performing a clinical study with listeriosis patients from a 2014 outbreak with Dr. C. Fariñas (Infectious Section-HUMV) and Dr. Martinez (Microbiology Dpt-HUMV) and Biodonostia Group of Microbiologists (col. Dr. E. Trallero, Dr. J. Marimon and Dr. CG. Cilla) to elaborate a human vaccine for patients at high risk of listeriosis.

3.- Listeria based dendritic vaccines loaded with peptides against melanoma (IP: Dr. C. Alvarez Dominguez y Dra. S. Yañez Diaz/Proyectos: SAF2009-08695 y SAF2012-34203 y Estudio Clínicos aprobado: CEIC-Acta 30/2012). Se utiliza una vacuna DC basada en Listeria cargada con el péptido LLO91-99 como terapia anti-adhesiva para el melanoma en modelos murinos (col. Dr. J. Gomez-Roman, S. Anatomia Patologica) y preparar en pacientes con melanomas una vacuna DC anti-melanoma en colaboración con los Servicios de Oncología y Dermatología del HUMV (melanoma metastatico) (cols. Dr. H. Fernandez-Llaca y Dra. A. Garcia) y el Grupo de Melanoma Humano de UPV (col. Dra. D. Boyano Lopez).

4.- Listeria based Nanovaccines and their applications. (PI: Dr. C. Alvarez Dominguez, Dr. S. Gomez Salces and Dr. S. Yañez Diaz/Grants: SAF2012-34203, and Approved Clinical Study: CEIC-Acta 1/2016-2015.177). In this study we used as vaccine vectors gold glyconanoparticles (AuGNP) of 2 nm size conjugated to Listeria peptides, LLO91-99 and GAPDH1-22. The group of CIC-biomaGUNE collaborates with our group preparing AuGNP (cols. Dr. M. Marradi, Dr. I. Garcia and Dr. S. Penades). We have performed studies with a prophylactic experimental nanovaccine against listeriosis and a non-pathogenic tuberculosis model. The efficiency of nanovaccine is based in their targeting to dendritic cells, lack of toxicity, biocompatibility and induction of a cytotoxic cellular immune response. Other applications with these Nanovaccines and their modifications are tumor therapies.

Gobierno de Cantabria  Servicio Cántabro de Salud  Hospital Universitario Marqués de Valdecilla   Universidad de Cantabria    Instituto de Salud Carlos III 
INSTITUTO DE INVESTIGACIÓN MARQUÉS DE VALDECILLA
Edificio IDIVAL, Avenida Cardenal Herrera Oria s/n,
39011 Santander (CANTABRIA).

Phone.: 942 31 55 15
Fax: 942 31 55 17

 

  • LINKS


EVENTS
events